Hoffmann-La Roche: Carcinoma, Hepatocellular trials
The registry lists 21 Carcinoma, Hepatocellular studies with Hoffmann-La Roche as lead sponsor. 1 are open to participants now and 6 have results posted.
Phase 1 7Phase 2 4Phase 3 7No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeRecruitingNCT07284121
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaTerminatedNCT05908786Phase 1/2Results posted
- A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic TherapyTerminatedNCT04732286Phase 3Results posted
- A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-AmethistaCompletedNCT04487067Phase 3Results posted
- A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic MetastasesCompletedNCT04338685Phase 1Results posted
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Phase 3Results posted
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Phase 3Results posted
- A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250
- A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisActive, not recruitingNCT06096779Phase 2
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Phase 3
- A Phase I Study of ERY974 in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05022927Phase 1
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Phase 3
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Phase 3
- A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
- A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)CompletedNCT03232593
- A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver CancerCompletedNCT02576964Phase 2
- A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)CompletedNCT02564614Phase 1
- A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular CarcinomaCompletedNCT01897038Phase 1
- A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT01507168Phase 2
- A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular CarcinomaCompletedNCT01308723Phase 1
- Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)CompletedNCT00976170Phase 1